Granulocyte colony-stimulating factor potentiates all-trans retinoic acid-induced granulocytic differentiation in acute promyelocytic leukemia cell line HT93A

详细信息    查看全文

• 作者：Yoshihito Uchino ; Noriyoshi Iriyama ; Yoshihiro Hatta…
• 关键词：Granulocyte colony ; stimulating factor ; All ; trans retinoic acid ; Differentiation ; Signal transducer and activator of transcription ; Ruxolitinib ; HT93A
• 刊名：Cancer Cell International
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：15
• 期：1
• 全文大小：1,670 KB
• 参考文献：1. Pébusque, MJ, Lafage, M, Lopez, M, Mannoni, P (1988) Preferential response of acute myeloid leukemias with translocation involving chromosome 17 to human recombinant granulocyte colony-stimulating factor. Blood 72: pp. 257-65
  2. Souza, LM, Boone, TC, Gabrilove, J, Lai, PH, Zsebo, KM, Murdock, DC (1986) Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 232: pp. 61-5 CrossRef
  3. Ohno, R, Tomonaga, M, Kobayashi, T, Kanamaru, A, Shirakawa, S, Masaoka, T (1990) Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 323: pp. 871-7 CrossRef
  4. Gu, L-F, Zhang, W-G, Wang, F-X, Cao, X-M, Chen, Y-X, He, A-L (2011) Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia. J Cancer Res Clin Oncol 137: pp. 997-1003 CrossRef
  5. Bug, G, Koschmieder, S, Krauter, J, Heuser, M, Thol, F, Wiebe, S (2014) Long-term results of a prospective randomized trial evaluating G-CSF priming in intensive induction chemotherapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia. Ann Hematol 93: pp. 193-202 CrossRef
  6. Fong, CY, Grigoriadis, G, Hocking, J, Coutsouvelis, J, Muirhead, J, Campbell, P (2013) Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse. Leuk Lymphoma 54: pp. 336-41 CrossRef
  7. Ramsingh, G, Westervelt, P, McBride, A, Stockerl-Goldstein, K, Vij, R, Fiala, M (2014) Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML. Int J Hematol 99: pp. 272-8 CrossRef
  8. Leonard, WJ (2001) Role of Jak kinases and STATs in cytokine signal transduction. Int J Hematol 73: pp. 271-7 CrossRef
  9. Murray, PJ (2007) The JAK-STAT signaling pathway: input and output integration. J Immunol 178: pp. 2623-9 CrossRef
  10. Beekman, R, Touw, IP (2010) G-CSF and its receptor in myeloid malignancy. Blood 115: pp. 5131-6 CrossRef
  11. Tian, SS, Tapley, P, Sincich, C, Stein, RB, Rosen, J, Lamb, P (1996) Multiple signaling pathways induced by granulocyte colony-stimulating factor involving activation of JAKs, STAT5, and/or STAT3 are required for regulation of three distinct classes of immediate early genes. Blood 88: pp. 4435-44
  12. Shimozaki, K, Nakajima, K, Hirano, T, Nagata, S (1997) Involvement of STAT3 in the granulocyte colony-stimulating factor-induced differentiation of myeloid cells. J Biol Chem 272: pp. 25184-9 CrossRef
  13. Tian, SS, Lamb, P, Seidel, HM, Stein, RB, Rosen, J (1994) Rapid activation of the STAT3 transcription factor by granulocyte colony-stimulating factor. Blood 84: pp. 1760-4
  14. Piccaluga, PP, Martinelli, G, Malagola, M, Rondoni, M, Bianchini, M, Visani, G (2003) Complete remission in acute myeloid leukemia with granulocyte-colony stimulating factor without chemotherapy. Report of cytogenetic remission of a t(9;11)(p22q23) positive AML patient and review of literature. Haematologica 88: pp. ECR28
  15. Deshpande, RV, Peterson, RH, Moore, MA (1997) Granulocyte colony-stimulating factor-induced activation of protein kinase-C in myeloid cells. J Cell Biochem 66: pp. 286-96 CrossRef
  16. Inazawa, Y, Saeki, K, Yuo, A (2003) Granulocyte colony-stimulating factor-induced terminal maturation of human
• 刊物主题：Cancer Research; Cell Biology;
• 出版者：BioMed Central
• ISSN：1475-2867

文摘

Background Granulocyte colony-stimulating factor (G-CSF) promotes proliferation, survival, and differentiation of myeloid-linage leukemic cells, as well as normal hematopoietic cells. Terminal granulocytic differentiation can be induced in acute promyelocytic (APL) cell line HT93A by G-CSF and all-trans retinoic acid (ATRA). Because the detailed mechanism has never been shown, we investigated the signal transduction pathway in granulocytic differentiation by G-CSF, alone or in combination with ATRA. Methods HT93A cell viability and growth were investigated by trypan blue exclusion assay. Cell differentiation was assessed by CD11b and CD34 expressions. Intracellular protein expressions were also evaluated by flow cytometry after fixation and permeabilization. Results ATRA (100 nM) induced granulocytic differentiation (upregulation of CD11b and downregulation of CD34) and the effect was potentiated by addition of G-CSF, while G-CSF alone had no effect on HT93A cells. The addition of G-CSF to ATRA had little or no effect on NB4 and THP-1 cells in comparison to ATRA alone. G-CSF receptor expression was reduced by ATRA treatment in a time-dependent manner. After 5?days-incubation with ATRA, the expression levels of signal transducer and activator of transcription (STAT) 3, and phosphorylated STAT3 and STAT5, were significantly reduced. STAT5 was strongly activated by G-CSF stimulation in ATRA-pretreated cells in comparison to untreated cells. In contrast, STAT3 showed no response to G-CSF. Janus kinase (JAK) inhibitor ruxolitinib (320 nM) had little or no effect on ATRA-induced differentiation, but eliminated the enhancing effect of G-CSF, as evidenced by the levels of CD11b and CD34 expression. These results suggest G-CSF activates STAT5 through the JAK pathway in combination with ATRA, resulting in myeloid differentiation in HT93A cells. Conclusions In conclusion, activation of the JAK-STAT pathway is likely essential for inducting differentiation in the APL cell line HT93A; thus, monitoring its expression and activation is important for predicting clinical efficacy and understanding the mechanisms of cytokine-dependent myelopoiesis, proliferation, and differentiation of acute myeloid leukemia.